Exchange: NASDAQ·Updated 07:59 PM EDT
News
all
press releases
BillionToOne (BLLN) Reports Q2 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for BillionToOne (BLLN) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks
More News
Does BillionToOne (BLLN) Have Another Major Growth Engine Beyond Prenatal Testing?
Does?BillionToOne?(BLLN) Have Another Major Growth Engine Beyond Prenatal Testing...
Yahoo! Finance: News
BillionToOne Appoints Ethan Dmitrovsky, MD, as Chief Medical Officer, Oncology, to Lead Medical Strategy for Northstar
BillionToOne Appoints Ethan Dmitrovsky, MD, as Chief Medical Officer, Oncology, to Lead Medical Strategy for Northstar BillionToOne Appoints Ethan Dmitrovsky, MD, as Chief Medical Officer, Oncology, to Lead Medical Strategy for Northstar PR Newswire MENLO PARK, Calif., July 20, 2026 Renowned...
PR Newswire
A BillionToOne Insider Sold 801 Shares as Revenue Jumped 84%
Key PointsAccording to a Form 4 filing, a BillionToOne executive sold 801 shares of Class A Common Stock at $124.91 per share for a total transaction value of $100,053 on July 1, 2026...
Nasdaq News: Markets
Billiontoone Reaches Analyst Target Price
In recent trading, shares of Billiontoone Inc (Symbol: BLLN) have crossed above the average analyst 12-month target price of $118.43, changing hands for $120.60/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on v...
Nasdaq News: Markets
Are Medical Stocks Lagging BillionToOne, Inc. (BLLN) This Year?
Here is how BillionToOne (BLLN) and Concentra Group (CON) have performed compared to their sector so far this year.
Zacks
BillionToOne's Northstar Response Is a Stronger Predictor of Immunotherapy Outcomes Than Standard-of-Care Imaging for Cancer Patients in Peer-Reviewed Study
BillionToOne's Northstar Response Is a Stronger Predictor of Immunotherapy Outcomes Than Standard-of-Care Imaging for Cancer Patients in Peer-Reviewed Study BillionToOne's Northstar Response Is a Stronger Predictor of Immunotherapy Outcomes Than Standard-of-Care Imaging for Cancer Patients in...
PR Newswire
Are Medical Stocks Lagging Biodesix (BDSX) This Year?
Here is how Biodesix, Inc. (BDSX) and BillionToOne (BLLN) have performed compared to their sector so far this year.
Zacks
Is BillionToOne, Inc. (BLLN) Stock Outpacing Its Medical Peers This Year?
Here is how BillionToOne (BLLN) and Eledon Pharmaceuticals, Inc. (ELDN) have performed compared to their sector so far this year.
Zacks
Does BillionToOne (BLLN) Have the Potential to Rally 37% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 37% in BillionToOne (BLLN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks

Advertisement|Remove ads.